Semler Dirty Data: EMA Suspends Over 200 Products; Stings Indian CROs
Executive Summary
Dirty data issues continue to plague Indian contract research organizations, denting the reputation of the beleaguered local industry and piling up challenges for marketing authorization holders. The European Medicines Agency (EMA) has now suspended close to 300 products that relied on flawed bioequivalence studies done by the Bengaluru-based Semler Research.
You may also be interested in...
EMA Recommends Dozens Of Suspensions Over Flawed Synchron Studies
The European Medicines Agency's human medicines committee has recommended the suspension of marketing authorizations for around 100 generics after identifying “irregularities” in how bioequivalence studies were conducted by Synchron Research Services.
EMA Recommends Dozens Of Suspensions Over Flawed Synchron Studies
The EMA’s CHMP has recommended the suspension of marketing authorizations for around 100 generics after identifying “irregularities” in how bioequivalence studies were conducted by Synchron Research Services.
Novartis' Zolgensma Had Manipulated Data In Application, US FDA Says
Gene therapy should remain on the market, FDA says, but Novartis could face civil or criminal penalties. Firm knew of problems before approval.